125
Participants
Start Date
October 31, 2006
Primary Completion Date
October 31, 2008
Study Completion Date
October 31, 2008
lanreotide (Autogel formulation)
120 mg administered via deep subcutaneous injection every 28 days over 28 weeks.
Pegvisomant
Administered at 40 to 120 mg per week via subcutaneous injection once or twice a week over 28 weeks.
Charite Campus Mitte, Berlin
Universitá di Torino, Torino
Hôpital de la Timone, Marseille
Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela
Anticancer Hospital Metaxa Piraeus, Piraeus
Universitá degli Studi di Milano, Milan
Clínica Puerta de Hierro, Madrid
CHU de Rangueil, Toulouse
Clinique Marc Linquette, Lille
Uppsala University Hospital, Uppsala
University Federico II, Napoli
Medizinische Klinik Innenstadt, München
Hôpital Bicêtre, Le Kremlin-Bicêtre
Klinikum Johann Wolfgang Goethe-Universität, Frankfurt
University Hospital, Charles University, Hradec Králové
Charles University, Prague
Aarhus Kommunehospital, Aarhus
Groupe Hospitalier Henri Mondor- Albert Chenevier, Créteil
Royal Hallamshire Hospital, Sheffield
Leiden University Medical Center, Leiden
Dept. of Internal Medicine Erasmus MC, Rotterdam
Hospital General de Alicante, Alicante
Sahlgrenska University Hospital, Gothenburg
Christie Hospital and Holt Radium Institute, Manchester
Lead Sponsor
Ipsen
INDUSTRY